




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan L. Epstein et al.)
)
Serial No.: 10/789,684)
)
Filed: February 27, 2004)
)
For: **VASOPERMEABILITY ENHANCING PEPTIDE**)
OF HUMAN INTERLEUKIN-2 AND)
IMMUNOCONJUGATES THEREOF)
)
Atty. Dkt. No.: 1920-325N1/09801297)
_____)

STATEMENT TO SUPPORT FILINGS AND SUBMISSIONS IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby certify that this correspondence is being transmitted by with the
U.S. Postal Service as Express Mail, Airbill No. EV 323472409 US, in an
envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on April 20, 2004.



Nancy Nolen

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


The undersigned, being attorney of record of the above-identified patent application, submits the following statement regarding the Sequence Listing in paper and computer readable form submitted herewith in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures for the above-captioned patent application, in accordance with 37 C.F.R. §§ 1.821 through 1.825:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) herein does not contain new matter.

Respectfully submitted,

Date: April 20, 2004


Margaret A. Churchill, Ph.D.
Registration No. 39,944
Attorneys for Applicants

Attorney Docket No. 1920-325N1/09801297
Telephone: (213) 892-9200
Facsimile: (213) 680-4518